ArticleFrontiers in cellular neuroscience2013
Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis.
Article in Frontiers in cellular neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Schizophrenia gene expression profile reverted to normal levels by antipsychotics.The international journal of neuropsychopharmacology · 2014Trial
- What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia.Biomolecules · 2024Review
- Biomarkers for Psychosis: Are We There Yet? Umbrella Review of 1478 Biomarkers.Schizophrenia bulletin open · 2024Article
- Whispers in the Blood: Leveraging MicroRNAs for Unveiling Autologous Blood Doping in Athletes.International journal of molecular sciences · 2023Review
- SELENBP1 overexpression in the prefrontal cortex underlies negative symptoms of schizophrenia.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Altered expression of the DISC1 gene in peripheral blood of patients with schizophrenia.BMC medical genetics · 2020Article
- The role of genetics in cognitive remediation in schizophrenia: A systematic review.Schizophrenia research. Cognition · 2020Review
- Altered expression of the CSMD1 gene in the peripheral blood of schizophrenia patients.BMC psychiatry · 2019Article
- Peripheral Biomarkers for First-Episode Psychosis-Opportunities from the Neuroinflammatory Hypothesis of Schizophrenia.Psychiatry investigation · 2019Article
- Altered Expression of a Unique Set of Genes Reveals Complex Etiology of Schizophrenia.Frontiers in psychiatry · 2019Article
- Anabolic Androgenic Steroids: Searching New Molecular Biomarkers.Frontiers in pharmacology · 2018Review
- Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort.Translational psychiatry · 2017Article
- Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations.Translational psychiatry · 2017Article
- The search for new biomarkers for cognition in schizophrenia.Schizophrenia research. Cognition · 2015Review
- Converging models of schizophrenia--Network alterations of prefrontal cortex underlying cognitive impairments.Progress in neurobiology · 2015Review
- Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation.Frontiers in cellular neuroscience · 2015Review
- Reduced mRNA expression of PTGDS in peripheral blood mononuclear cells of rapid-cycling bipolar disorder patients compared with healthy control subjects.The international journal of neuropsychopharmacology · 2014Article
- Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications.Dialogues in clinical neuroscience · 2014Review
- From attention to memory along the dorsal-ventral axis of the medial prefrontal cortex: some methodological considerations.Frontiers in systems neuroscience · 2014Review
- Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia.Neuropsychiatric disease and treatment · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-mortem brain investigations of schizophrenia have generated swathes of data in the last few decades implicating candidate genes and protein. However, the relation of these findings to peripheral biomarker indicators and symptomatology remain to be elucidated. While biomarkers for disease do not have to be involved with underlying pathophysiology and may be largely indicative of diagnosis or prognosis, the ideal may be a biomarker that is involved in underlying disease processes and which is therefore more likely to change with progression of the illness as well as potentially being more responsive to treatment. One of the main difficulties in conducting biomarker investigations for major psychiatric disorders is the relative inconsistency in clinical diagnoses between disorders such as bipolar and schizophrenia. This has led some researchers to investigate biomarkers associated with core symptoms of these disorders, such as psychosis. The aim of this review is to evaluate the contribution of post-mortem brain investigations to elucidating the pathophysiology pathways involved in schizophrenia and psychosis, with an emphasis on major neurotransmitter systems that have been implicated. This data will then be compared to functional neuroimaging findings as well as findings from blood based gene expression investigations in schizophrenia in order to highlight the relative overlap in pathological processes between these different modalities used to elucidate pathogenesis of schizophrenia. In addition we will cover some recent and exciting findings demonstrating microRNA (miRNA) dysregulation in both the blood and the brain in patients with schizophrenia. These changes are pertinent to the topic due to their known role in post-transcriptional modification of gene expression with the potential to contribute or underlie gene expression changes observed in schizophrenia. Finally, we will discuss how post-mortem studies may aid future biomarker investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.